Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans [3]

British Journal of Dermatology

Volumn 151, Issue 1, 2004, Pages 235-237

  Mizutani, K ^a   Tamada, Y ^a   Hara, K ^a   Tsuzuki, T ^b   Saeki, H ^c   Tamaki, K ^c   Matsumoto, Y ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; CANCER INHIBITION; CANCER PATIENT; CASE REPORT; DERMATOFIBROSARCOMA PROTUBERANS; DRUG RESPONSE; FIBROSARCOMA; HISTOLOGY; HUMAN; LETTER; LUNG CAPACITY; LUNG METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; HUMANS; LUMBOSACRAL REGION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4043068508     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06024.x     Document Type: Letter

References (10)

1. Menzel T, Beham A, Katenkamp D et al. Fibrosarcomatous (high-grade) dermatofibrosarcoma protuberans. Am J Surg Pathol 1998; 22: 576-87.
2. Pedeutour F, Simon MP, Minoletti F et al. Translocation t(17;22)(q22;q13) in dermatofibrosarcoma protuberans. A new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 1996; 72: 171-4.
3. Pedeutour F, Simon MP, Sozzi G et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995; 55: 2400-3.
4. Simon MP, Pedeutour F, Sirvent N et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15: 95-8.
5. Shimizu A, O'Brien KP, Sjoblom T et al. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59: 3719-23.
6. Sjoblom T, Shimizu A, O'Brien KP et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI-571 through induction of apoptosis. Cancer Res 2001; 61: 5778-83.
7. Hashimoto T, Fukui T, Tamada Y et al. A multiple lung metastatic case of dermatofibrosarcoma protuberans with fibrosarcomatous lesion. Jpn J Dermatol 2003; 113: 437-42 (in Japanese).
8. Saeki H, Hoashi T, Tada Y et al. Analysis of gene mutations in three cases of dermatofibrosarcoma protuberans (DFSP): ordinary DFSP, DFSP with fibrosarcomatous lesion (DFSP-FS) and lung metastasis of DFSP-FS. J Dermatol Sci 2003; 33: 161-7.
9. Maki RG, Awan RA, Dixon RH et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100: 623-6.
10. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20: 3586-91.